Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(R)-ND-336 is a highly potent and selective MMP-9 inhibitor, displaying a K i value of 19 nM. It also exhibits inhibitory activity against MMP-2 (K i = 127 nM) and MMP-14 (K i =119 nM). With its significant potential, (R)-ND-336 is being investigated in the field of diabetic foot ulcers (DFUs) research [1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 14,900 | 6-8周 | ||
50 mg | ¥ 19,420 | 6-8周 | ||
100 mg | ¥ 24,625 | 6-8周 |
产品描述 | (R)-ND-336 is a highly potent and selective MMP-9 inhibitor, displaying a K i value of 19 nM. It also exhibits inhibitory activity against MMP-2 (K i = 127 nM) and MMP-14 (K i =119 nM). With its significant potential, (R)-ND-336 is being investigated in the field of diabetic foot ulcers (DFUs) research [1]. |
体外活性 | (R)-ND-336 poorly inhibits other MMPs (K i >100 μM). (R)-ND-336 has a long residence time (the time the inhibitor is bound to MMP-9, calculated as 1/k off ) of 300 min [1]. A favorable IC50value of 143 μM afforded a therapeutic index (IC 50 /K i for MMP-9) ratio of 7530, indicating that (R)-ND-336 is not cytotoxic [1]. |
体内活性 | (R)-ND-336 (50 μg/wound/day for 14 days) accelerates wound healing faster [1]. (R)-ND-336 has an AUC of 1.3 μM min after topical administration and 35 μM min following intravenous dosing, for an AUC top /AUC iv ratio of 3.7%, indicating minimal absorption after topical administration in db/db mice [1]. Animal Model: Female db/db mice (BKS.Cg-Dock7 m+/+ Lepr db /J, 8-weeks old, ~40 g body weight) [1] Dosage: 50 μg Administration: Wound; once a day for 14 days Result: Accelerated wound healing faster and showed complete inhibition of MMP-9. |
分子量 | 371.89 |
分子式 | C16H18ClNO3S2 |
CAS No. | 2252493-33-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(R)-ND-336 2252493-33-5 Inhibitor inhibitor inhibit